Alebund Pharmaceuticals (Jiangsu) Limited has published the Terms of Reference governing its newly established Strategy Committee, a body designed to support the Board of Directors in shaping long-term strategy and overseeing major investments.

The committee will comprise a minimum of three directors, all nominated by either the Board chairman, a majority of independent non-executive directors, or at least one-third of the full Board, and then elected by the Board. The Board chairman will concurrently serve as committee chair. Each member’s tenure will match the Board’s term; members leaving the Board will automatically vacate their committee seats and be replaced through the same nomination process.

Mandated responsibilities include: • Evaluating and advising on the company’s long-term strategic development plans. • Assessing major investment and financing initiatives, capital operations, and asset management projects that require Board approval. • Monitoring execution of approved strategic initiatives. • Providing recommendations on other significant corporate matters as stipulated by laws, regulations, the company’s Articles of Association, or Board authorization.

The Strategy Committee operates under defined procedures: • The Board office coordinates preliminary analyses, gathers feasibility studies, and submits formal proposals to the committee. • Meetings are convened at the request of the Board or the committee chair, with a minimum three-day notice—waivable by unanimous consent. • A quorum requires two-thirds of members; resolutions pass with a simple majority. • Members must disclose any conflicts of interest and abstain from voting where appropriate. • Minutes are retained for ten years, and written reports of resolutions are submitted to the Board.

The committee can invite directors and senior management to attend meetings and may engage external advisers at the company’s expense. Confidentiality obligations apply to all participants.

These terms take effect from Alebund Pharmaceuticals’ initial public offering of H shares and listing on the Main Board of The Stock Exchange of Hong Kong Limited. Any future amendments will be subject to Board approval and aligned with prevailing laws, regulations, and the company’s Articles of Association.